NCT07335211

Brief Summary

A multicenter, randomized, single-blind, active controlled, phase III clinical trial to evaluate the efficacy and safety of HUC3-637 in patients with primary open angle glaucoma or ocular hypertension

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
206

participants targeted

Target at P25-P50 for phase_3

Timeline
19mo left

Started Jan 2026

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress18%
Jan 2026Dec 2027

Study Start

First participant enrolled

January 1, 2026

Completed
4 days until next milestone

First Submitted

Initial submission to the registry

January 5, 2026

Completed
8 days until next milestone

First Posted

Study publicly available on registry

January 13, 2026

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2027

Last Updated

January 13, 2026

Status Verified

January 1, 2026

Enrollment Period

1.8 years

First QC Date

January 5, 2026

Last Update Submit

January 11, 2026

Conditions

Primary Open Angle Glaucoma (POAG)Ocular Hypertension

Outcome Measures

Primary Outcomes (1)

  • Mean change in diurnal IOP

    12 week

Study Arms (2)

HUC3-637

EXPERIMENTAL

Dorzolamide, Timolol

Drug: HUC3-637

HUC3-637-R

ACTIVE COMPARATOR

Dorzolamide, Timolol

Drug: HUC3-637-R

Interventions

HUC3-637DRUG

Ophthalmic solution instilled directly into the eye (topical ocular administration)

HUC3-637
HUC3-637-RDRUG

Ophthalmic solution instilled directly into the eye (topical ocular administration)

HUC3-637-R

Eligibility Criteria

Age19 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Adults aged 19 years and older
  • Participants diagnosed with POAG or OH
  • Have fully explained and understood the study and have voluntarily given written informed consent.

You may not qualify if:

  • Acute or chronic angle-closure glaucoma
  • Congenital glaucoma, secondary glaucoma (open-angle glaucoma)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kangbuk Samsung Hospital

Seoul, South Korea

RECRUITING

MeSH Terms

Conditions

Glaucoma, Open-AngleOcular Hypertension

Condition Hierarchy (Ancestors)

GlaucomaEye Diseases

Central Study Contacts

Rang Lee

CONTACT

07074926091rlee@huons.com

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 5, 2026

First Posted

January 13, 2026

Study Start

January 1, 2026

Primary Completion (Estimated)

November 1, 2027

Study Completion (Estimated)

December 1, 2027

Last Updated

January 13, 2026

Record last verified: 2026-01

Data Sharing

IPD Sharing
Will not share

Locations

KR(1)